Terns Pharmaceuticals

TERN

Market cap $4.81B

New position: 375,000 shares added; estimated trade size ~$15.15 million based on quarterly average price Quarter-end position value increased by $15.15 million, reflecting both trading activity and stock price movement Position accounts for a 3.32% change in Boxer Capital's 13F reportable assets under management Post-trade holding: 375,000 shares valued at $15.15 million TERN enters Boxer Capital's portfolio as a new position but is not among the fund's top five holdings

FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be participating in the following upcoming investor conferences in March.

ORBIMED Advisors LLC reduced stake by 5,409,671 shares in Terns Pharmaceuticals; the estimated trade size is $125.01 million based on quarterly average price Quarter-end position value decreased by $30.20 million, reflecting both trading and share price movement Transaction represented 2.55% of fund's 13F reportable AUM Post-trade position: 2,153,300 shares, valued at $86.99 million Stake now makes up 1.78% of fund AUM, placing it outside the fund's top five holdings These 10 Stocks Could Mint the Next Wave of Millionaires ›

First Turn Management acquired 872,049 shares in Terns Pharmaceuticals during the fourth quarter. The quarter-end Terns Pharmaceuticals position value increased by $35.23 million, reflecting both the new stake and stock price movements.

The consensus price target hints at a 50.9% upside potential for Terns Pharmaceuticals (TERN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

FOSTER CITY, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of February 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended.

“Big mo” is an “eternal feature” of financial markets worldwide.

Terns Pharmaceuticals, Inc. (TERN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL data by 2H26, and initiation of 2L+ pivotal trial in late 2026/early 2027 TERN-701 was granted U.S. FDA Fast Track designation for the treatment of CML in Q4 2025 Year-end 2025 unaudited cash, cash equivalents and marketable securities of approximately $1.0 billion, expected to provide runway into 2031 FOSTER CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that management will provide an update on 2026 priorities and program milestones during the Company's presentation at the 44th Annual J.P.

FOSTER CITY, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of January 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended.